18 and older, any sex, with Inflammatory Lung Injury or Ischemia-Reperfusion Lung Injury. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha (pg/mL)Primary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Inflammatory mediator found in BAL fluid during lung inflammation
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
0.53
0.53 – 4.99
Intravenous Anesthesia
0.53
0.53 – 13.80
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
22.06
1.75 – 623.08
Intravenous Anesthesia
102.04
2.21 – 408.05
Difference
Group
Value
95% CI
Inhaled Anesthesia
17.24
1.22 – 536.77
Intravenous Anesthesia
101.51
1.47 – 402.84
Number of Patients With Postoperative Pulmonary ComplicationsSecondary· Assessed daily, beginning on the first day after surgery, until hospital discharge or death. On average at our institution, most patients are discharged within 7 days so this is the expected time frame for follow up.
Composite endpoint of clinically relevant pulmonary complications
Prolonged intubation (greater than 48hrs)
Group
Value
95% CI
Inhaled Anesthesia
0
Intravenous Anesthesia
3
Failed extubation (re-intubated within 24hrs)
Group
Value
95% CI
Inhaled Anesthesia
0
Intravenous Anesthesia
1
Reintubation (greater than 24hrs after extubation)
Group
Value
95% CI
Inhaled Anesthesia
0
Intravenous Anesthesia
2
Pulmonary edema
Group
Value
95% CI
Inhaled Anesthesia
4
Intravenous Anesthesia
8
Pleural effusion
Group
Value
95% CI
Inhaled Anesthesia
17
Intravenous Anesthesia
21
Atelectasis
Group
Value
95% CI
Inhaled Anesthesia
16
Intravenous Anesthesia
19
Infiltrate/consolidation
Group
Value
95% CI
Inhaled Anesthesia
6
Intravenous Anesthesia
6
Pneumothorax
Group
Value
95% CI
Inhaled Anesthesia
1
Intravenous Anesthesia
5
BAL Concentration of IL1b (pg/mL)Secondary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Inflammatory mediator found in BAL fluid during lung inflammation
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
0.42
0.06 – 2.61
Intravenous Anesthesia
0.87
0.28 – 2.54
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
8.56
0.21 – 64.77
Intravenous Anesthesia
14.37
1.88 – 76.10
Difference
Group
Value
95% CI
Inhaled Anesthesia
8.30
-0.67 – 59.64
Intravenous Anesthesia
11.00
1.18 – 66.14
BAL Concentration of IL6 (pg/mL)Secondary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Inflammatory mediator found in BAL fluid during lung inflammation
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
30.70
6.77 – 96.60
Intravenous Anesthesia
31.35
5.27 – 165.93
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
275.19
6.21 – 1134.33
Intravenous Anesthesia
297.35
40.59 – 1277.04
Difference
Group
Value
95% CI
Inhaled Anesthesia
220.68
-12.41 – 1046.00
Intravenous Anesthesia
259.32
30.33 – 1039.58
BAL Concentration of IL8 (pg/mL)Secondary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Inflammatory mediator found in BAL fluid during lung inflammation
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
2008.50
341.25 – 16444.75
Intravenous Anesthesia
6528.50
625.00 – 16332.25
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
8019.50
998.25 – 100438.00
Intravenous Anesthesia
27789.50
4780.50 – 154087.75
Difference
Group
Value
95% CI
Inhaled Anesthesia
4701.00
-290.25 – 77061.00
Intravenous Anesthesia
16230.00
1399.25 – 123098.50
BAL Concentration of MCP1 (pg/mL)Secondary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Inflammatory mediator found in BAL fluid during lung inflammation
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
509.50
249.25 – 1415.75
Intravenous Anesthesia
977.50
336.50 – 1225.75
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
496.00
184.25 – 2153.25
Intravenous Anesthesia
883.50
651.50 – 4380.50
Difference
Group
Value
95% CI
Inhaled Anesthesia
148.00
-265.75 – 869.75
Intravenous Anesthesia
479.50
-104.25 – 1482.75
BAL Concentration of sRAGE (pg/mL)Secondary· Change from baseline and 2-4 hours after exposure to cardiopulmonary bypass
Biomarker of lung injury (RAGE - receptor for advance glycosylation end products)
Pre-Bypass
Group
Value
95% CI
Inhaled Anesthesia
156.50
44.00 – 383.00
Intravenous Anesthesia
164
60.75 – 380.50
Post-Bypass
Group
Value
95% CI
Inhaled Anesthesia
597.00
220.50 – 1195.00
Intravenous Anesthesia
465.00
206.00 – 2120.50
Difference
Group
Value
95% CI
Inhaled Anesthesia
402.50
155.25 – 1063.25
Intravenous Anesthesia
224.50
-69.25 – 2088.25
Adverse events — posted to ClinicalTrials.gov
Time frame: During hospital length of stay ~7 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Inhaled Anesthesia
Serious: 0/18 (0%)
Deaths: 0/18
Intravenous Anesthesia
Serious: 0/22 (0%)
Deaths: 1/22
Other adverse events (12 terms — click to expand)
Reaction
System
Inhaled Anesthesia
Intravenous Anesthesia
Pleural effusion
Respiratory, thoracic and mediastinal disorders
—
—
Atelectasis
Respiratory, thoracic and mediastinal disorders
—
—
Hypoxia (PaO2/FiO2 < 300)
Respiratory, thoracic and mediastinal disorders
—
—
Respiratory acidosis (PaCO2 > 45)
Respiratory, thoracic and mediastinal disorders
—
—
Pulmonary edema
Respiratory, thoracic and mediastinal disorders
—
—
Infiltrate/consolidation
Respiratory, thoracic and mediastinal disorders
—
—
Pneumothorax
Respiratory, thoracic and mediastinal disorders
—
—
Prolonged intubation (greater than 48hrs)
Respiratory, thoracic and mediastinal disorders
—
—
Reintubation (greater than 24hrs after extubation)
The purpose of this study is to investigate whether the use of inhaled anesthetics, compared to intravenous anesthetics, can affect the amount of lung inflammation and postoperative respiratory complications seen after cardiac surgery.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07525648 — Comparison of the Effects of Sevoflurane and Desflurane on Optic Nerve Sheath Diameter During Laparoscopic Surgery
· NA
· recruiting
NCT07511634 — Comparison of Sevoflurane and Desflurane on ANI in Patients Undergoing General Anesthesia: a Prospective Randomized Cont
· NA
· not yet recruiting
NCT07440758 — Low-Flow Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy
· NA
· not yet recruiting
NCT07295158 — Effect of Sevoflurane vs Desflurane on Mechanical Power in Laparoscopic Cholecystectomy
· NA
· recruiting
NCT07152912 — Impact of Isoflurane and Sevoflurane on Oxidative Stress in Patients Undergoing Laparoscopic Cholecystectomy
· NA
· recruiting
Other Beth Israel Deaconess Medical Center trials
Trials by the same sponsor.
NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)
· NA
· not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function
· NA
· not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an
· NA
· not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study
· NA
· enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 5 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02918877.